Taiko Pharmaceutical Co (TSE:4574) Cyclically Adjusted Revenue per Share: 円0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
68 GF Score
Price 円255.00
GF Value 円339.28
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Taiko Pharmaceutical Co TSE:4574 +2.41% 68 Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus rates TSE:4574 with a GF Score™ of 68/100 and a GF Value™ of 円339.28 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Taiko Pharmaceutical Co's adjusted revenue per share for the three months ended in Dec. 2025 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Taiko Pharmaceutical Co was 6.30% per year. The lowest was 3.40% per year. And the median was 4.85% per year.

As of today (2026-07-30), Taiko Pharmaceutical Co's current stock price is 円255.00. Taiko Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was 円0.00. Taiko Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Taiko Pharmaceutical Co was 12.25. The lowest was 1.00. And the median was 2.58.


Taiko Pharmaceutical Co  (TSE:4574) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Taiko Pharmaceutical Co was 12.25. The lowest was 1.00. And the median was 2.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Taiko Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Taiko Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 254.32 254.58 247.23 0.00 0.00

Taiko Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 243.31 241.66 0.00 0.00 0.00

TSE:4574 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4574
68GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Taiko Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Taiko Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 72.563 98.100 83.584
201603 55.308 97.900 63.839
201606 26.939 98.100 31.031
201609 46.822 98.000 53.989
201612 72.543 98.400 83.306
201703 52.345 98.100 60.295
201706 32.798 98.500 37.626
201709 52.299 98.800 59.816
201712 72.144 99.400 82.015
201803 64.050 99.200 72.960
201806 29.653 99.200 33.778
201809 58.316 99.900 65.963
201812 79.366 99.700 89.953
201903 74.069 99.700 83.950
201906 32.958 99.800 37.317
201909 69.889 100.100 78.896
201912 132.466 100.500 148.942
202003 113.656 100.300 128.047
202006 131.344 99.900 148.567
202009 118.325 99.900 133.841
202012 0.000 99.300 0.000
202103 75.650 99.900 85.570
202106 42.716 99.500 48.512
202109 74.803 100.100 84.443
202112 53.280 100.100 60.146
202203 14.249 101.100 15.926
202206 28.325 101.800 31.441
202209 35.130 103.100 38.503
202212 37.881 104.100 41.120
202303 26.761 104.400 28.965
202306 27.708 105.200 29.762
202309 38.989 106.200 41.485
202312 34.094 106.800 36.073
202403 27.458 107.200 28.944
202406 29.545 108.200 30.856
202412 0.000 110.700 0.000
202503 22.961 111.100 23.354
202506 25.128 111.700 25.420
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
Taiko Pharmaceutical Co (TSE:4574) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Taiko Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円0.00. Overall, Taiko Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Taiko Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円339.28, compared to a current price of 円255.00 — trading 24.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. Taiko Pharmaceutical Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円255.00 is trading 24.8% below its estimated GF Value™ of 円339.28. GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4574:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円339.28 vs. price of 円255.00 (24.8% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
68GF Score

Get the complete analysis for TSE:4574

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円255.00
Price
円339.28
GF Value